You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Identifying secondary AML (sAML)

AML with myelodysplasia-related changes (AML-MRC)1

WHO defines AML-MRC as ≥20% blasts in the peripheral blood or bone marrow and any of the following2,3:

AML-MRC patient cased

AML-MRC patient

Name

Jerry

Age

61

Search icon

Diagnosis

AML with myelodysplasia-related changes

Folder icon

History

No prior major medical diagnosis

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

IMPORTANT SAFETY INFORMATION

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Important Safety Information

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.